ZIIHERA Approval Signals Rising Complexity in HER2 Biologics Manufacturing

Jazz Pharmaceuticals Ireland Limited secured FDA accelerated approval for ZIIHERA (zanidatamab-hrii) on November 20, 2024, positioning bispecific HER2-directed antibody technology at the center of an increasingly complex biologics manufacturing landscape. For contract manufacturers and QA directors managing HER2-directed pipelines, the approval signals that bispecific antibody platforms are moving from clinical novelty to commercial-scale reality, with all the process validation and sterility assurance demands that entails.

ZIIHERA is indicated for adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer, as detected by an FDA-approved companion diagnostic test. The drug is administered via intravenous infusion once every two weeks by a healthcare professional. The companion diagnostic requirement introduces an additional layer of supply chain coordination that QA and regulatory affairs teams will need to account for in commercial launch planning.

FDA granted accelerated approval based predominantly on evidence from Cohort 1 of the HERIZON-BTC-01 trial (NCT04466891). The open-label, multicenter, single-arm study enrolled 80 patients with previously treated unresectable or metastatic HER2-positive BTC across 32 sites in 9 countries, including the United States, Canada, France, the United Kingdom, China, and the Republic of Korea. Efficacy analyses focused on the 62 patients within Cohort 1 who demonstrated high HER2 expression (IHC 3+). Only 17 of the 80 trial participants were treated in the United States, a demographic distribution that regulatory affairs leads should note when evaluating post-market commitments under accelerated approval pathways.

The single-arm trial design, standard for accelerated approval submissions in rare oncology indications, measured objective response rate, duration of response, progression-free survival, and overall survival. Patients were required to have received at least one prior gemcitabine-containing systemic chemotherapy regimen and to have adequate cardiac function defined as left ventricular ejection fraction of 50% or greater. The cardiac function eligibility criterion is a relevant safety signal for pharmacovigilance teams building risk management frameworks around HER2-directed biologics.

ZIIHERA's approval adds to a growing roster of bispecific antibodies requiring manufacturers to demonstrate robust process controls under 21 CFR Part 211 and ICH Q10 quality management principles. As the bispecific antibody class expands into additional oncology indications, the manufacturing and analytical method complexity associated with dual-targeting constructs will continue to test existing GMP infrastructure across both innovator and contract manufacturing organizations. Source: FDA Drug Trials Snapshots, ZIIHERA, published April 29, 2026.